Statins inhibit endogenous cholesterol production by competitive inhibition of HMG-CoA reductase (HMGCR), the enzyme that catalyzes conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol synthesis. This pathway delineates genes involved in statin pharmacogenomics, including genes involved in mediating the effects of statins on plasma lipoprotein metabolism. Sources: [https://www.pharmgkb.org/pathway/PA2031 PharmGKB] and [http://en.wikipedia.org/wiki/Statin Wikipedia]

Authors

Nathan Salomonis , Kristina Hanspers , Bruce Conklin , Alex Pico , Thomas Kelder , Martina Summer-Kutmon , Andra Waagmeester , Egon Willighagen , Daniela Digles , and Eric Weitz

Cited In

• 
• 
• 

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organism

Mus musculus

Communities

Annotations

Pathway Ontology: statin drug pathway hypercholesterolemia pathway

Disease Ontology: cardiovascular system disease

Participants

References

1. Chen H, Ikeda U, Shimpo M, Shimada K. Direct effects of statins on cells primarily involved in atherosclerosis. Hypertens Res. 2000 Mar;23(2):187–92. PubMed Europe PMC Scholia